⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920698 | 0.75 | — | — | |
| SCHEMBL4705599 | 0.71 | — | — | |
| SCHEMBL1831075 | 0.69 | — | — | |
| SCHEMBL19724899 | 0.69 | — | — | |
| SCHEMBL23114037 | 0.69 | — | — | |
| SCHEMBL101460 | 0.69 | — | — | |
| SCHEMBL2288386 | 0.69 | — | — | |
| SCHEMBL15140889 | 0.69 | — | — | |
| SCHEMBL25338300 | 0.69 | — | — | |
| SCHEMBL773461 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| CN-117083274-A | Fused ring heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-3500556-B1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022223022-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223022-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-10-27 | — | — | WO | disclosed |
| EP-2781519-B1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME | ST PHARM CO LTD (KR) | 2019-10-30 | — | — | EP | disclosed |
| EP-3500556-A1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10143681-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018039094-A1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2013073875-A1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME | 한국화학연구원 (KR) | 2013-05-23 | — | — | WO | disclosed |
| EP-2029540-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7659287-B2 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659287-B2 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659287-B2 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-2029540-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | Amgen Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007145834-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |